Welcome : Guest

Vertex Pharmaceuticals, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Vertex Pharmaceuticals, Inc., which is principally involved in Biotechnology Business. Illustrated with 95 tables, the report showcases the company's sales performance, key markets and market position as against its competitors operating in the industry.

Code: PCP-01525
Price: $3500
Company Type: Public
Pages: 98
Date: November 2016
Market Data Tables: 95

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Table 1: Vertex Pharmaceuticals, Inc.’s Sales by Product Category Worldwide (2015) in Percentage for Product Revenues (Kalydeco, Orkambi, Incivek), Royalty Revenues, and Collaborative Revenues......3
Table 2: Vertex Pharmaceuticals, Inc.’s Sales by Geographic Region Worldwide (2014-2015) in Percentage for United States, Europe, and Others......4
Table 3: Vertex Pharmaceuticals, Inc.’s Sales by Product Segment Worldwide (2013-2014) in Percentage for KALYDECO, Product, and INCIVEK Product......5
Table 4: Vertex Pharmaceuticals, Inc.’s Sales by Geographic Region Worldwide (2013-2014) in Percentage for United States, Europe and Others......6
Biotechnology......8
Table 5: Biotechnology Market by Category in China (2015) - Percentage Share Breakdown by Value for Biopharmaceutical and Chemical......8
Table 6: Biotechnology Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Biopharmaceutical and Chemical......9
Biotechnology Drugs......10
Table 7: Biotechnology Drugs by Type Worldwide (2015) - Percentage Market Share Breakdown by Value for Cell Therapy, Gene Therapy, Monoclonal Antibodies (MAB), Recombinant Hormones and Proteins, Vaccines, and Others......10
Biopharmaceuticals......11
Table 8: Biopharmaceuticals Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Norditropin, NovoSeven, Turoctocog Alpha, and Others......11
Cystic Fibrosis (CF)......12
Table 9: Cystic Fibrosis (CF) Patient Population by Region Worldwide (2015) - Percentage Share Breakdown by Value for Australia, Canada, Rest of Europe, United Kingdom and USA......12
Table 10: Drugs for Treatment of Cystic Fibrosis Market Worldwide (2015) in US$ Million......13
Table 11: Molecular Cystic Fibrosis (CF) Testing Market by Assay in the US (2015) - Percentage Share Breakdown by Value Sales for Cystic Fibrosis Genotyping, eSensor® Cystic Fibrosis, InPlex® Cystic Fibrosis (CF), Laboratory Developed Tests and xTAG® Cystic Fibrosis......14
Cancer Drugs......15
Table 12: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......15
Table 13: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......16
Cancer Market......17
Table 14: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others*......17
Table 15: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......18
Table 16: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......19
Table 17: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......20
Table 18: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......21
Table 19: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......22
Table 20: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......23
Table 21: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......24
Cancer Patients......25
Table 22: Breast Cancer Diagnoses by Hospital Type in the US (2015) - Percentage Share Breakdown by Volume for Community, Comprehensive, Teaching and Research, and Others......25
Table 23: No. of Colorectal Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......26
Table 24: No. of Invasive Breast Cancer Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......27
Table 25: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......28
Table 26: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......29
Table 27: No. of Cutaneous Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......30
Table 28: No. of Ocular Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......31
Table 29: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......32
Table 30: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......33
Table 31: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......34
Table 32: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......35
Table 33: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......36
Table 34: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......37
Table 35: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......38
Table 36: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......39
Table 37: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......40
Table 38: No. of Bladder Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Invasive Patients, and Non-Invasive Patients......41
Table 39: No. of Invasive Breast Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......42
Table 40: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......43
Table 41: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......44
Table 42: No. of Non Small Cell Lung Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I, Stage II-III, Stage III-IV, and Undiagnozed......45
Cervical Cancer......46
Table 43: Cervical Cancer Market by HPV Type in England (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 33, HPV 45, and Others......46
Table 44: Cervical Cancer Market by HPV Type in Europe (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 31, HPV 33, and Others......47
Hematological Cancer......48
Table 45: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......48
Skin Cancer......49
Table 46: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......49
Cancer-Associated Mucositis......50
Table 47: Cancer-Associated Mucositis Market by Activity Worldwide (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Head and Neck, Non-Small Cell Lung cancer and Others......50
Chronic Myelogenous Leukemia (CML)......51
Table 48: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......51
Multiple Myeloma......52
Table 49: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......52
Table 50: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......53
Pain Drugs......54
Table 51: Pain Drugs Market by Type in the US (2015) - Percentage Share Breakdown by Value for Fentanyl, Hydrocordone, Acetaminophen, Lidoderm, Lyrica, OpanaER, Oxycotin, and Others......54
Inflammatory Bowel Disease (IBD) Drugs......55
Table 52: Inflammatory Bowel Disease (IBD) Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Anti-Inflammatory, Biologics, and Immunomodulatory......55
Spinal Cord Injuries (SCI)......56
Table 53: Spinal Cord Injury Market by Payer in the US (2015) - Percentage Share Breakdown by Value for Medicaid, Medicare, and Private Insurance......56
Table 54: No. of Spinal Cord Injuries (SCI) by Cause Worldwide (2015) - Percentage Market Share Breakdown for Falls, Sports, Vehicular, Violence, and Others......57
Hepatitis B......58
Table 55: No. of Hepatitis B Patients by Region in Europe (2015) - Percentage Market Share Breakdown by Volume for Eastern Europe, and Western Europe......58
Table 56: No. of Hepatitis B Patients by Country in Eastern Europe (2015) - Percentage Market Share Breakdown by Volume for Hungary, Poland, and Romania......59
Table 57: No. of Hepatitis B Patients by Country in West Europe (2015) - Percentage Market Share Breakdown by Volume for France, Germany, Italy, Netherlands, Spain, United Kingdom, and Others......60
Hepatitis C......61
Table 58: Hepatitis C Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Immuno Modulator, Polymerase Inhibitor, Protease Inhibitors, and Others* (Includes Ribavirin)......61
Table 59: Hepatitis C Market by Genotype Worldwide (2015) - Percentage Share Breakdown by Value for Genotype 1, Genotype 2 and Others......62
Table 60: Hepatitis C Virus Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Immuno-Modulator, Polymerase Inhibitor, Protease Inhibitors, Ribavirin, and Others......63
Table 61: Hepatitis C Virus Market by Patient Conditions in Europe (2015) - Percentage Share Breakdown by Value for Diagnosed, Prevalence, Under Care and Others......64
Table 62: No. of Hepatitis C Virus (HCV) Patients by Category in European Union (EU) (2015) - Percentage Market Share Breakdown for GT1, and Non-GT1......65
Table 63: Hepatitis C Virus Market by Patient Conditions in the US (2015) - Percentage Share Breakdown by Value for Diagnosed, Prevalence, Under Care and Others......66
Table 64: Health Insurance for Hepatitis C Virus (HCV) by Type in the US (2015) - Percentage Market Share Breakdown by Value for Commercial, Dual (Medicare and Medicaid), Medicaid, Medicare (Non- Dual), Prison, Uninsured, and Veteran Affairs......67
Table 65: No. of Hepatitis C Virus (HCV) Patients by Category in the US (2015) - Percentage Market Share Breakdown for GT1 HCV, GT2/3 HCV, and Others......68
Chronic Obstructive Pulmonary Disease (COPD) Drugs......69
Table 66: Chronic Obstructive Pulmonary Disease (COPD) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for Europe, North America and Rest of the World......69
Table 67: Chronic Obstructive Pulmonary Disease (COPD) Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value Sales for Long Acting Muscarinic Antagonists (LAMA), Long Acting Muscarinic Antagonists (LAMA) and Long Acting β2-Agonists (LABA), and Long Acting β2-Agonists (LABA) and Inhaled Corticosteroid (ICS)......70
Table 68: No. of Chronic Obstructive Pulmonary Disease (COPD) Patients Worldwide (2015) - Percentage Market Share Breakdown for Europe, North America, and Rest of World......71
Table 69: Chronic Obstructive Pulmonary Disease (COPD) and Asthma Market by Product Worldwide (2015) - Percentage Share Breakdown by Value for Flixotide and Flovent, Seretide and Advair, Spiriva, Symbicort, Xolair, and Others......72
Neurology......73
Table 70: Neurology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Cerebrospinal Fluid Management, Interventional Neuroradiology, Neurostimulation, Neurosurgery, and Neurovascular Catheters......73
Biotechnology......74
Table 71: Market Shares of Leading Biotechnology Companies Worldwide (2015) - Percentage Breakdown by Value for Amgen, Inc., Merck KGaA, Monsanto Company, Roche Holding AG, Syngenta AG, and Others......74
Table 72: Market Shares of Leading Agricultural Biotechnology Companies Worldwide (2015) - Percentage Breakdown by Research and Development (R&D) Expenditure for Bayer CropScience AG, Dow AgroSciences LLC, DuPont Pioneer, Monsanto Co., Inc., Syngenta AG and Others......75
Table 73: Market Shares of Leading Biotechnology Companies in China (2015) - Percentage Share Breakdown by Value for F. Hoffmann-La Roche Ltd., MERCK SERONO CO., LTD., Novo Nordisk A/S, Qilu Pharmaceutical Co., Ltd. and Others......76
Biopharmaceuticals......77
Table 74: Market Shares of Leading Biopharmaceutical Companies Worldwide (2014) - Percentage Breakdown by Volume (Installed Capacity) for Amgen Inc., Biogen Idec, Inc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Ltd., Lonza Group Ltd., Pfizer, Inc., Sanofi S.A., and Others......77
Table 75: Market Shares of Leading Biopharmaceutical Companies in the US (2015) - Percentage Market Share Breakdown by Value for Actelion Pharmaceuticals Ltd., Alexion Pharmaceuticals, Inc., Celgene Corporation, Gilead Sciences, Inc., Incyte, Corporation, Isis Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc., and Others......78
Cancer Drugs......79
Table 76: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......79
Table 77: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......80
Table 78: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......81
Table 79: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......82
Table 80: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......83
Breast Cancer Drugs......84
Table 81: Market Shares of Leading Breast Cancer Drugs by Value Sales in China (2014) - Percentage Breakdown for Alkylating Agents, Antimetabolite, Antitumor Antibiotics, Antitumor Antihormone, Antitumor Botanicals, Monoclonal Antibodies, Targeted Small Molecule Agents, and Others......84
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......85
Table 82: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......85
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......86
Table 83: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......86
Table 84: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Others......87
Pain Management Drugs......88
Table 85: Market Shares of Leading Pain Management Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AstraZeneca Plc, Endo International Plc, Johnson & Johnson, Pfizer, Inc., and Others......88
Table 86: Market Shares of Leading Pain Remedies Manufacturers for Over-the-Counter (OTC) Sector in the US (2015) - Percentage Breakdown by Value for Bayer HealthCare AG, Johnson & Johnson Private Limited, Pfizer, Inc., Prestige Brands Holdings, Inc., Private-label and Others......89
Table 87: Market Shares of Leading Pain Remedy Producers Sales in the US OTC Market (2014) - Percentage Breakdown by Value for Bayer AG, Johnson & Johnson, Novartis AG, Pfizer, Inc., Prestige Brands Holdings, Inc., Private Label and Others......90
Table 88: Market Shares of Leading Oral Pain Relief Brands through Food Store in the US (2015) - Percentage Share Breakdown by Value for Anbesol, Baby Orajel, Kank A, Kank A Softbrush, Orajel, Private Label, and Others......91
Table 89: Market Shares of Leading Oral Pain Relief Brands through Supermarkets, Drugstores, Mass Merchandisers (including Wal-Mart), Gas & Convenience Stores, Military Commissaries, and Select Club and Dollar Retail Chains in the US (2015) - Percentage Share Breakdown by Value for Anbesol, BabyOrajel, Hyland's, KankA, Orajel, and Others......92
Table 90: Market Shares of Leading Oral Pain Remedy Brands by Value Sales through Supermarkets, Drug Stores and Mass Merchandisers (excluding Wal-Mart) in the US (2015) - Percentage Share Breakdown for Anbesol, Baby Orajel, Glyoxide, Kank-A, Orajel, Private Label, and Others......93
Influenza Vaccine......94
Table 91: Market Shares of Leading Influenza Vaccine Manufacturers by Value Sales in India (2014) - Percentage Breakdown for GlaxoSmithKline Plc (Fluarix), and Others......94
HBV/HCV Therapeutics......95
Table 92: Market Shares of Leading HBV/HCV Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., and Others......95
Table 93: Market Shares of Leading Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) Drugs Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for Bristol-Myers Squibb Co (BMY), GlaxoSmithKline Plc (GSK), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Vertex Pharmaceuticals, Inc. (VRTX), and Others......96
Table 94: Vertex Pharmaceuticals, Inc.’s Sales by Geographic Region Worldwide (2013) in Percentage for United States, Europe and Others......97
Table 95: Vertex Pharmaceuticals Inc.’s Revenue by Product Segment Worldwide (2011-2013) in US$ Thousands for Product Revenues, Net, Royalty Revenues and Collaborative Revenues......98